Tag: obstructive hypertrophic cardiomyopathy

Bristol Myers Squibb wraps up $13.1bn acquisition of MyoKardia

pharmanewsdaily- November 18, 2020

Bristol Myers Squibb has wrapped up its previously announced $13.1 billion acquisition of MyoKardia, a California-based clinical-stage biopharma company. Following the closing of the deal, ... Read More

Bristol Myers Squibb to acquire MyoKardia to gain access to mavacamten

pharmanewsdaily- October 5, 2020

Bristol Myers Squibb (BMS) has agreed to acquire California-based clinical-stage biopharma company MyoKardia for $13.1 billion, to gain access to the latter’s cardiovascular drug candidate ... Read More